EP3969610A2 - Kit, system, and flow cell - Google Patents
Kit, system, and flow cellInfo
- Publication number
- EP3969610A2 EP3969610A2 EP21707071.3A EP21707071A EP3969610A2 EP 3969610 A2 EP3969610 A2 EP 3969610A2 EP 21707071 A EP21707071 A EP 21707071A EP 3969610 A2 EP3969610 A2 EP 3969610A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- capture
- enrichment
- solid support
- channel
- beads
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 claims abstract description 171
- 239000011324 bead Substances 0.000 claims abstract description 141
- 239000007787 solid Substances 0.000 claims abstract description 136
- 108020004414 DNA Proteins 0.000 claims abstract description 124
- 102000053602 DNA Human genes 0.000 claims abstract description 124
- 238000002360 preparation method Methods 0.000 claims abstract description 122
- 239000012530 fluid Substances 0.000 claims abstract description 61
- 230000000295 complement effect Effects 0.000 claims abstract description 40
- 239000012634 fragment Substances 0.000 claims description 103
- 238000000034 method Methods 0.000 claims description 82
- 150000007523 nucleic acids Chemical group 0.000 claims description 74
- 239000000758 substrate Substances 0.000 claims description 69
- 230000003321 amplification Effects 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 39
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 29
- 239000002299 complementary DNA Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 11
- 238000004891 communication Methods 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 11
- 239000011521 glass Substances 0.000 claims description 10
- 230000000903 blocking effect Effects 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 230000005684 electric field Effects 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 99
- 239000013615 primer Substances 0.000 description 95
- 238000012163 sequencing technique Methods 0.000 description 94
- 239000000017 hydrogel Substances 0.000 description 40
- 125000003729 nucleotide group Chemical group 0.000 description 37
- 239000002773 nucleotide Substances 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 30
- 239000000126 substance Substances 0.000 description 28
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 229920002477 rna polymer Polymers 0.000 description 24
- 229960002685 biotin Drugs 0.000 description 22
- 239000011616 biotin Substances 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 22
- 108010090804 Streptavidin Proteins 0.000 description 19
- -1 analogs thereof Substances 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 102000008579 Transposases Human genes 0.000 description 15
- 108010020764 Transposases Proteins 0.000 description 15
- 235000020958 biotin Nutrition 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 150000001345 alkine derivatives Chemical class 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 230000017105 transposition Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000010899 nucleation Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 7
- 239000013614 RNA sample Substances 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000007639 printing Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 6
- 238000000151 deposition Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 229920006322 acrylamide copolymer Polymers 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 108010012306 Tn5 transposase Proteins 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000011901 isothermal amplification Methods 0.000 description 4
- 238000000813 microcontact printing Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000004528 spin coating Methods 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010061833 Integrases Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000005229 chemical vapour deposition Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000003618 dip coating Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000007641 inkjet printing Methods 0.000 description 3
- 238000002218 isotachophoresis Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000001127 nanoimprint lithography Methods 0.000 description 3
- 102000044158 nucleic acid binding protein Human genes 0.000 description 3
- 108700020942 nucleic acid binding protein Proteins 0.000 description 3
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 229910052814 silicon oxide Inorganic materials 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229910001936 tantalum oxide Inorganic materials 0.000 description 3
- PBCFLUZVCVVTBY-UHFFFAOYSA-N tantalum pentoxide Inorganic materials O=[Ta](=O)O[Ta](=O)=O PBCFLUZVCVVTBY-UHFFFAOYSA-N 0.000 description 3
- 238000007740 vapor deposition Methods 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 2
- 238000005698 Diels-Alder reaction Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229910052581 Si3N4 Inorganic materials 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000011358 absorbing material Substances 0.000 description 2
- 150000003926 acrylamides Chemical class 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 238000012733 comparative method Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007606 doctor blade method Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910000449 hafnium oxide Inorganic materials 0.000 description 2
- WIHZLLGSGQNAGK-UHFFFAOYSA-N hafnium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Hf+4] WIHZLLGSGQNAGK-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 2
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical group CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 2
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002907 paramagnetic material Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 229920002120 photoresistant polymer Polymers 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001748 polybutylene Polymers 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000007650 screen-printing Methods 0.000 description 2
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000034005 thiol-disulfide exchange Effects 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- PHIYHIOQVWTXII-UHFFFAOYSA-N 3-amino-1-phenylpropan-1-ol Chemical compound NCCC(O)C1=CC=CC=C1 PHIYHIOQVWTXII-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- NHWNVPNZGGXQQV-UHFFFAOYSA-J [Si+4].[O-]N=O.[O-]N=O.[O-]N=O.[O-]N=O Chemical compound [Si+4].[O-]N=O.[O-]N=O.[O-]N=O.[O-]N=O NHWNVPNZGGXQQV-UHFFFAOYSA-J 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000002902 ferrimagnetic material Substances 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 150000003961 organosilicon compounds Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 238000000678 plasma activation Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011342 resin composition Substances 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 150000004905 tetrazines Chemical class 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00698—Measurement and control of process parameters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/149—Particles, e.g. beads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
- C12Q2565/631—Detection means characterised by use of a special device being a biochannel or pore
Definitions
- Flow cells are used in a variety of methods and applications, such as gene sequencing, genotyping, etc.
- DNA double-stranded DNA
- dsDNA double-stranded DNA
- the purpose is to generate smaller DNA molecules (e.g., DNA fragments) from larger dsDNA molecules for use as templates in DNA sequencing reactions.
- the templates may enable short read lengths to be obtained.
- overlapping short sequence reads can be aligned to reconstruct the longer nucleic acid sequences.
- pre-sequencing steps (such as barcoding of particular nucleic acid molecules) can be used to simplify the data analysis.
- a first aspect disclosed herein is a kit, comprising: a library preparation fluid including library preparation beads, each library preparation bead including a first solid support and a transposome attached to the first solid support; a sample fluid including a genomic deoxyribonucleic acid sequence; and an enrichment fluid including target capture beads, each target capture bead including a second solid support and capture probes attached to the second solid support, each of the capture probes including a single stranded deoxyribonucleic acid sequence that is complementary to a targeted region of the genomic deoxyribonucleic acid in the sample fluid.
- a second aspect disclosed herein is another kit, comprising: an RNA to cDNA conversion sub-kit; and an enrichment fluid including target capture beads, each target capture bead including a solid support and capture probes attached to the solid support, each of the capture probes including a single stranded deoxyribonucleic acid sequence that is complementary to a targeted region of cDNA generated using the RNA to cDNA conversion sub-kit.
- a third aspect disclosed herein is a system, comprising: a substrate; a preparation channel defined at a first region on the substrate, the preparation channel including preparation capture sites to immobilize library preparation beads; an enrichment channel defined at a second region on the substrate downstream of the preparation channel, the enrichment channel including amplification primers and enrichment capture sites to immobilize target capture beads; and a transport channel selectively and fluidically connecting the preparation channel and the enrichment channel.
- a fourth aspect disclosed herein is a flow cell, comprising: an enrichment channel defined between two surfaces, the enrichment channel including amplification primers attached to at least one of the two surfaces and target capture beads immobilized on the at least one of the two surfaces, each target capture bead including a solid support and capture probes attached to the solid support, each of the capture probes including a single stranded nucleic acid sequence that is complementary to a targeted region of a genomic deoxyribonucleic acid or of a complementary deoxyribonucleic acid.
- a fifth aspect disclosed herein is a method, comprising introducing target capture beads into an enrichment channel including at least one surface containing amplification primers and enrichment capture sites, whereby at least some of the target capture beads become immobilized at the enrichment capture sites, each of the target capture beads including a solid support and capture probes attached to the solid support, each of the capture probes including a single stranded nucleic acid sequence that is complementary to a targeted region of a genomic deoxyribonucleic acid or of a complementary deoxyribonucleic acid.
- FIG. 1 A is a top view of an example of a flow cell
- Fig. 1 B is an enlarged, cross-sectional view, taken along the 1 B-1 B line of Fig. 1 A, of an example of an enrichment channel and non-patterned sequencing surfaces;
- Fig. 1C is an enlarged, cross-sectional view, taken along the 1C-1C line of Fig. 1 A, of an example of an enrichment channel and patterned sequencing surfaces;
- FIG. 2 is a schematic flow diagram illustrating an example library preparation method
- FIG. 3A is a schematic flow diagram illustrating another example library preparation method
- FIG. 3B is a schematic illustration of the bridges resulting from the method of Fig. 3A redrawn for clarity;
- FIG. 4 is a schematic illustration of an example system including an example of a flow cell having on-board library preparation chambers;
- FIG. 5 is a schematic illustration depicting an example of an enrichment method disclosed herein;
- Fig. 6 is a graph depicting the relative coverage plot of target library fragments on a flow cell surface when a comparative enrichment method is used, and when an example enrichment method is used; and [0019] Fig. 7 is a bar graph depicting the targeted cluster count for target capture beads with different probe densities.
- Some sequencing techniques utilize capture primers on the surface of a flow cell in order to capture and amplify DNA library fragments.
- Flow cell architectures and amplification processes may be utilized to generate individual monoclonal populations of amplicons of respective DNA library fragments in different areas of the flow cell. This may be desirable when analyzing all or a large portion of a DNA sample (from which the DNA library fragments are generated), as each monoclonal population can provide lots of data for each of the DNA library fragments.
- the target portion or region of interest may be enriched, e.g., which helps to separate the target portion from the remainder of the DNA sample. This enables the sequencing reads to be dedicated to the target portion.
- the enrichment technique disclosed herein utilizes on-flow cell hybridization and capture of the library fragments that correspond to the target portion.
- these terms can refer to less than or equal to ⁇ 10% from a stated value, such as less than or equal to ⁇ 5% from a stated value, such as less than or equal to ⁇ 2% from a stated value, such as less than or equal to ⁇ 1 % from a stated value, such as less than or equal to ⁇ 0.5% from a stated value, such as less than or equal to ⁇ 0.2% from a stated value, such as less than or equal to ⁇ 0.1 % from a stated value, such as less than or equal to ⁇ 0.05% from a stated value.
- Adapter A linear oligonucleotide sequence that can be fused to a nucleic acid molecule, for example, by ligation or tagmentation.
- the adapter may be a tag exhibiting a sequence for an intended purpose.
- the adapter can exhibit a sequence that is complementary to at least a portion of a primer, for example, a primer including a universal nucleotide sequence (such as a P5 or P7 sequence).
- a transposome complex may include a polynucleotide having a 3’ portion comprising a transposon end sequence, and an adapter comprising one or more regions suitable for hybridization with a primer for a cluster amplification reaction.
- the adapter at one end of a fragment includes a sequence that is complementary to at least a portion of a first flow cell primer, and the adapter at the other end of the fragment includes a sequence that is identical to at least a portion of a second flow cell primer.
- the complementary adapter can hybridize to the first flow cell primer, and the identical adapter is a template for its complementary copy, which can hybridize to the second flow cell primer during clustering.
- the adapter can include a sequencing primer sequence or sequencing binding site (e.g., one or more regions suitable for hybridization with a primer for a sequencing reaction). Combinations of different adapters may be incorporated into a nucleic acid molecule, such as a DNA fragment.
- Suitable adapter lengths may range from about 10 nucleotides to about 100 nucleotides, or from about 12 nucleotides to about 60 nucleotides, or from about 15 nucleotides to about 50 nucleotides.
- the adapter may include any combination of nucleotides and/or nucleic acids.
- Capture Probe A single stranded deoxyribonucleic acid sequence that is complementary to a targeted region of a genomic deoxyribonucleic acid, or of a complementary deoxyribonucleic acid derived from a ribonucleic acid sample.
- Capture Site A portion of a flow cell surface having been modified with a chemical property that allows for localization of a specific material (e.g., target capture beads, complexes, protein biomarkers, etc.).
- the capture site may include a chemical capture agent (i.e., a material, molecule or moiety) that is capable of attaching, retaining, or binding to a specific molecule.
- a chemical capture agent i.e., a material, molecule or moiety
- One example chemical capture agent includes a member of a receptor-ligand binding pair (e.g., avidin, streptavidin, biotin, lectin, carbohydrate, nucleic acid binding protein, epitope, antibody, etc.) that is capable of binding to the specific material (or to a linking moiety attached to the specific material).
- the chemical capture agent is a chemical reagent capable of forming an electrostatic interaction, a hydrogen bond, or a covalent bond (e.g., thiol-disulfide exchange, click chemistry, Diels-Alder, etc.) with the specific material.
- Capture sites that are designed to attach target capture beads are referred to herein as “enrichment capture sites.”
- Capture sites that are designed to attach solid supports for library preparation are referred to herein as “preparation capture sites.”
- Depositing Any suitable application technique, which may be manual or automated, and, in some instances, results in modification of the surface properties. Generally, depositing may be performed using vapor deposition techniques, coating techniques, grafting techniques, or the like. Some specific examples include chemical vapor deposition (CVD), spray coating (e.g., ultrasonic spray coating), spin coating, dunk or dip coating, doctor blade coating, puddle dispensing, flow through coating, aerosol printing, screen printing, microcontact printing, inkjet printing, or the like.
- CVD chemical vapor deposition
- spray coating e.g., ultrasonic spray coating
- spin coating dunk or dip coating
- doctor blade coating puddle dispensing
- Depression A discrete concave feature in a substrate or a patterned resin having a surface opening that is at least partially surrounded by interstitial region(s) of the substrate or the patterned resin.
- Depressions can have any of a variety of shapes at their opening in a surface including, as examples, round, elliptical, square, polygonal, star shaped (with any number of vertices), etc.
- the cross-section of a depression taken orthogonally with the surface can be curved, square, polygonal, hyperbolic, conical, angular, etc.
- the depression can be a well or two interconnected wells.
- the depression may also have more complex architectures, such as ridges, step features, etc.
- Enrichment channel An area defined between two bonded or otherwise attached components, which includes target capture beads immobilized therein, or can receive and immobilize target capture beads therein.
- the enrichment channel may be defined between two patterned or non-patterned sequencing surfaces, and thus may be in fluid communication with one or more components of the sequencing surfaces.
- Flow Cell A vessel having a chamber (e.g., which may include an enrichment channel) where a reaction can be carried out, an inlet for delivering reagent(s) to the chamber, and an outlet for removing reagent(s) from the chamber.
- the chamber enables the detection of the reaction that occurs in the chamber.
- the chamber can include one or more transparent surfaces allowing for the optical detection of arrays, optically labeled molecules, or the like.
- Nucleic acid molecule or sample A polymeric form of nucleotides of any length, and may include ribonucleotides, deoxyribonucleotides, analogs thereof, or mixtures thereof. The term may refer to single stranded or double stranded polynucleotides.
- a “template” nucleic acid molecule may refer to a sequence that is to be analyzed.
- the nucleotides in a nucleic acid sample may include naturally occurring nucleic acids and functional analogs thereof. Examples of functional analogs are capable of hybridizing to a nucleic acid in a sequence specific fashion or capable of being used as a template for replication of a particular nucleotide sequence.
- Naturally occurring nucleotides generally have a backbone containing phosphodiester bonds.
- An analog structure can have an alternate backbone linkage including any of a variety known in the art.
- Naturally occurring nucleotides generally have a deoxyribose sugar (e.g., found in DNA) or a ribose sugar (e.g., found in RNA).
- An analog structure can have an alternate sugar moiety including any of a variety known in the art.
- Nucleotides can include native or non-native bases.
- a native DNA can include one or more of adenine, thymine, cytosine and/or guanine
- a native RNA can include one or more of adenine, uracil, cytosine and/or guanine.
- Any non-native base may be used, such as a locked nucleic acid (LNA) and a bridged nucleic acid (BNA).
- LNA locked nucleic acid
- BNA bridged nucleic acid
- Primer A nucleic acid molecule that can hybridize to a specific sequence.
- an amplification primer can hybridize to an adapter attached to a library fragment, and can serve as a starting point for template amplification and cluster generation.
- a synthesized nucleic acid (template) strand may include a site to which a primer (e.g., a sequencing primer) can hybridize in order to prime synthesis of a new strand that is complementary to the synthesized nucleic acid strand.
- Any primer can include any combination of nucleotides or analogs thereof.
- the primer is a single-stranded oligonucleotide or polynucleotide.
- the primer length can be any number of bases long and can include a variety of non-natural nucleotides.
- the sequencing primer is a short strand, ranging from 10 to 60 bases, or from 20 to 40 bases.
- each adapter includes a known universal sequence (e.g., which is complementary to or identical to at least a portion of a primer on a flow cell) and a sequencing primer sequence. Both of the adapters may also include an index (barcode or tag) sequence.
- one side e.g., including a P5’ or P5 sequence
- the other side including a P7 or P7’ sequence
- Sequencing surface A polymeric hydrogel having one or more types of amplification primers grafted thereto.
- the sequencing surface may also include an enrichment capture agent to immobilize target capture beads.
- Solid support A small body made of a rigid or semi-rigid material having a shape characterized, for example, as a sphere, oval, microsphere, or other recognized particle shape whether having regular or irregular dimensions. Some examples of the solid support can have library fragments attached thereto. Other examples of the solid support can have capture probes attached thereto.
- Target Capture Bead A solid support having capture probes attached thereto.
- Target Library Fragment A single stranded portion of i) a genomic deoxyribonucleic acid sequence or ii) a complementary deoxyribonucleic acid derived from a ribonucleic acid sample.
- the sequence of the target library fragment is complementary to the capture probes of the target capture bead.
- the sequence of the target library fragment may be a region of interest, e.g., a specific genomic panel, such as exomes or tumor related genes.
- Transferred Strand A transferred portion of two transposon ends.
- non-transferred strand refers to the non-transferred portion of two transposon ends.
- the 3’ -end of a transferred strand is joined or transferred to target DNA in an in vitro transposition reaction.
- the non-transferred strand which exhibits a transposon end sequence that is complementary to the transferred transposon end sequence, is not joined or transferred to the target DNA in an in vitro transposition reaction.
- the transferred strand and non-transferred strand are covalently joined.
- the transferred and non- transferred strand sequences are provided on a single oligonucleotide, e.g., in a hairpin configuration.
- the non- transferred strand becomes attached to the DNA fragment indirectly, because the non-transferred strand is linked to the transferred strand by the loop of the hairpin structure.
- Transposon End A double-stranded nucleic acid DNA that exhibits only the nucleotide sequences (the “transposon end sequences”) that are necessary to form the complex with a transposase or integrase enzyme that is functional in an in vitro transposition reaction.
- a transposon end is capable of forming a functional complex with the transposase in a transposition reaction.
- transposon ends can include the 19-base pair (bp) outer end (“OE”) transposon end, the inner end (“IE”) transposon end, or the “mosaic end” (“ME”) transposon end recognized by a wild-type or mutant Tn5 transposase.
- Transposon ends can include any nucleic acid or nucleic acid analogue suitable for forming a functional complex with the transposase or integrase enzyme in an in vitro transposition reaction.
- the transposon end can include DNA, RNA, modified bases, non-natural bases, modified backbone, and can comprise nicks in one or both strands.
- DNA may be used throughout the present disclosure in connection with the composition of transposon ends, it should be understood that any suitable nucleic acid or nucleic acid analogue can be utilized in a transposon end.
- Transposase An enzyme that is capable of forming a functional complex with a transposon end-containing composition (e.g., transposons, transposon ends, transposon end compositions) and catalyzing insertion or transposition of the transposon end-containing composition into the double-stranded target DNA with which it is incubated, for example, in an in vitro transposition reaction.
- a transposase as presented herein can also include integrases from retrotransposons and retroviruses.
- Tn5 transposase and/or hyperactive Tn5 transposase any transposition system that is capable of inserting a transposon end with sufficient efficiency to 5’ -tag and fragment a target DNA for its intended purpose can be used.
- a preferred transposition system is capable of inserting the transposon end in a random or in an almost random manner to 5’ -tag and fragment the target DNA.
- Transposome Complex A transposase enzyme non-covalently bound to a double stranded nucleic acid.
- the transposome complex can be a transposase enzyme pre-incubated with double-stranded transposon DNA under conditions that support non-covalent complex formation.
- Double-stranded transposon DNA can include, for example, Tn5 DNA, a portion of Tn5 DNA, a transposon end composition, a mixture of transposon end compositions or other double-stranded DNAs capable of interacting with a transposase, such as the hyperactive Tn5 transposase.
- target capture beads are utilized in the enrichment channel of the flow cell, which also includes sequencing surface(s).
- the target capture beads include capture probes, which are capable of selectively capturing library fragments of interest. Therefore, the target capture beads enable custom enrichment to take place within the flow cell.
- the target capture beads are shown in Fig. 1 B and Fig. 1 C at reference numeral 36.
- the target capture beads 36 include a solid support 38 and capture probes 40 attached to the solid support.
- the solid support 38 may be, without limitation, glass (e.g., controlled pore glass beads); magnetically responsive materials; plastic, such as acrylic, polystyrene or a copolymer of styrene and another material, polypropylene, polyethylene, polybutylene, polyurethane or polytetrafluoroethylene (TEFLON® from The Chemours Co); polysaccharides or cross-linked polysaccharides such as agarose or SEPHAROSE® beads (cross-linked beaded form of agarose, available from Cytivia); nylon; nitrocellulose; resin; silica or silica-based materials including silicon and modified silicon; carbon-fiber; metal; inorganic glass; an optical fiber bundle; or a variety of other polymers.
- glass e.g., controlled pore glass beads
- plastic such as acrylic, polystyrene or a copolymer of styrene and another material, polypropylene, polyethylene, polybutylene, polyurethane or
- a “magnetically responsive” material is responsive to a magnetic field.
- magnetically responsive solid supports include or are composed of magnetically responsive materials.
- magnetically responsive materials include paramagnetic materials, ferromagnetic materials, ferrimagnetic materials, and metamagnetic materials.
- suitable paramagnetic materials include iron, nickel, and cobalt, as well as metal oxides, such as Fe 3 0 4 , BaFe 12 0i 9 , CoO, NiO, Mn 2 C>3, Cr 2 0 3 , and CoMnP.
- One commercially available example includes DYNABEADSTM M-280 Streptavidin (superparamagnetic beads coated with streptavidin) from ThermoFisher Scientific.
- the magnetically responsive material is embedded in the shell of a polymer bead.
- the magnetically responsive material is in bead form and is coated with a passivating material, such as silicon oxide or silicon nitrite.
- any example of the solid support 38 may have the form of solid beads, porous beads, or hollow beads.
- the solid support 38 may be functionalized with one member of a binding pair.
- a “binding pair” refers to two agents (e.g., materials, molecules, moieties) that are capable of attaching to one another.
- the member on the solid support 38 is a binding pair with another member that is located on the sequencing surface (see 12, 12’ in Fig. 1 B and 14, 14’ of Fig. 1C) of the flow cell 10 (Fig. 1A).
- the member on the solid support 38 may be multi-functional in that it can i) bind to a member attached to the capture probes 40, and ii) bind to an enrichment capture site (see 32, 32’ in Fig. 1 B and Fig.
- the solid support 38 may be functionalized with two different binding pair members, e.g., i) one member that can bind to the member attached to the capture probes 40, and ii) another member that can bind to the enrichment capture site 32, 32’ on the 12, 12’ or 14, 14’ of the flow cell 10.
- Functionalization of the solid support 38 may involve coating the solid support 38 with the binding pair member, or forming a bond between the binding pair member and a functional group at the surface of the solid support 38.
- a binding pair member includes a member of a receptor-ligand binding pair (e.g., avidin, streptavidin, biotin, lectin, carbohydrate, nucleic acid binding protein, epitope, antibody, etc.) that is capable of binding to the other binding pair member that is located on the sequencing surface of the flow cell.
- the binding pair members may also be chemical reagents that are capable of forming an electrostatic interaction, a hydrogen bond, or a covalent bond (e.g., thiol-disulfide exchange, click chemistry, Diels-Alder, etc.).
- the solid support 38 does not include a member of a binding pair, but rather, the solid support 38 may be capable of being chemically conjugated to the enrichment capture site 32, 32’. Any form of chemical coupling may be used to attach the solid support 38 to the enrichment capture site 32, 32’. [0059] In many instances, a reversible or cleavable interaction is desirable between the solid support 38 and the enrichment capture site 32, 32’ so that the target capture beads 36 may be removed prior to sequencing.
- the target capture beads 36 also include capture probes 40 attached to the solid support 38.
- Each capture probe 40 on the solid support 38 includes the same single stranded deoxyribonucleic acid sequence. This sequence is selected so that each capture probe 40 selectively hybridizes to a target library fragment, which includes a sequence of interest (e.g., that is to be analyzed).
- the capture probe sequence is complementary to a targeted region of the genomic deoxyribonucleic acid.
- the capture probe sequence is complementary to a complementary deoxyribonucleic acid (cDNA) derived from a targeted region of a ribonucleic acid sample.
- cDNA complementary deoxyribonucleic acid
- the number of nucleotides in a capture probe 40 may depend upon the number of nucleotides in the target library fragment. In some instances, the capture probe 40 is smaller than the target library fragment.
- the capture probe 40 may include from about 50 nucleotides to about 200 nucleotides. In one example, the capture probe 40 includes from about 80 nucleotides to about 120 nucleotides. In another example, the capture probe 40 includes 69 nucleotides.
- the capture probes 40 may be prepared using any oligonucleotide synthesis technique.
- One end of the capture probe 40 may be bound to the other member of the binding pair so that it can bind to the member attached to the solid support 38.
- the capture probe 40 may be biotinylated to bind with streptavidin at the surface of the solid support 38.
- the capture probes 40 may be attached to the solid support 38 by incubating the solid supports 38 in a mixture containing the capture probes 40.
- the capture probes 40 may be mixed into a salt buffer. Any suitable salt buffer that facilitates or enables the reaction between the capture probe 40 and the solid support 38 may be used.
- the salt buffer may facilitate the biotin- streptavidin reaction so that biotinylated capture probes 40 bind to the streptavidin on the solid supports 38.
- the salt buffer is an aqueous solution including sodium chloride, sodium citrate, or combinations thereof. In one specific example, the salt buffer includes about 0.75 M sodium chloride and about 75 mM sodium citrate in water.
- the number of capture probes 40 in the mixture may depend upon the number of solid supports 38 to be added to the mixture and the desired probe density for the target capture beads 36.
- the desired probe density of the target capture beads 36 ranges from about 2 * 10 5 capture probes per solid support to about 5 * 10 6 capture probes per solid support.
- the capture probe density of the target capture beads 36 may be controlled by adjusting a concentration of the capture probes in the mixture used for incubation.
- One example method for forming the target capture beads 36 includes synthesizing the capture probes 40 with a first member of a binding pair attached to an end of each capture probe 40; and incubating the capture probes 40 with the solid support 38, wherein the solid support 38 is coated with a second member of the binding pair.
- the target capture beads 36 may be used in flow cells 10 with patterned sequencing surfaces 14, 14’ or non-patterned sequencing surfaces 12, 12’. It is to be understood that the target capture beads 36 may include any example of the solid support 38 and the capture probes 40 described herein.
- FIG. 1A A top view of an example of the flow cell 10 is shown in Fig. 1A.
- some examples of the flow cell 10 include two sequencing opposed sequencing surfaces.
- An example of non- patterned sequencing surfaces 12, 12’ are shown in Fig. 1 B, and an example of patterned sequencing surfaces 14, 14’ are shown in Fig. 1C.
- Each sequencing surface 12, 12’ or 14, 14’ is supported by a substrate (generally shown as 16 in Fig. 1A), and an enrichment channel (generally shown as 18 in Fig. 1A) is defined between the sequencing surfaces 12, 12’ or 14, 14’.
- the flow cell 10 includes one sequencing surface supported by a substrate 16 and a lid attached to the substrate 16. In these examples, the enrichment channel 18 is defined between the sequencing surface 12 or 14 and the lid.
- the substrate 16 may be a single layer/material.
- Examples of the single layer substrate are shown at reference numeral 16A and 16A’ in Fig. 1 B.
- suitable single layer substrates 16A, 16A include epoxy siloxane, glass, modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, polytetrafluoroethylene (such as TEFLON® from Chemours), cyclic olefins/cyclo-olefin polymers (COP) (such as ZEONOR®from Zeon), polyimides, etc.), nylon (polyamides), ceramics/ceramic oxides, silica, fused silica, or silica-based materials, aluminum silicate, silicon and modified silicon (e.g., boron doped p+ silicon), silicon nitride (Si 3 N 4
- the substrate 16 may also be a multi-layered structure. Examples of the multi-layered substrate are shown at reference numeral 16B and 16B’ in Fig. 1C. Some examples of the multi-layered structure 16B, 16B’ include glass or silicon, with a coating layer of tantalum oxide or another ceramic oxide at the surface. With specific reference to Fig. 1C, other examples of the multi-layered structure 16B,
- 16B’ include an underlying support 20, 20’ having a patterned resin 22, 22’ thereon. Still other examples of the multi-layered substrate 16B, 16B’ may include a silicon- on-insulator (SOI) substrate.
- SOI silicon- on-insulator
- the substrate 16 may have a diameter ranging from about 2 mm to about 300 mm, or a rectangular sheet or panel having its largest dimension up to about 10 feet ( ⁇ 3 meters).
- the substrate 16 is a wafer having a diameter ranging from about 200 mm to about 300 mm.
- the substrate 16 is a die having a width ranging from about 0.1 mm to about 10 mm. While example dimensions have been provided, it is to be understood that a substrate 16 with any suitable dimensions may be used.
- a panel may be used that is a rectangular support, which has a greater surface area than a 300 mm round wafer.
- the flow cell 10 includes enrichment channels 18. While several enrichment channels 18 are shown, it is to be understood that any number of channels 18 may be included in the flow cell 10 (e.g., a single channel 18, four channels 18, etc.). In some of the examples disclosed herein, each enrichment channel 18 is an area defined between two sequencing surfaces (e.g., 12 and 12’ or 14 and 14’) and by two attached substrates (e.g., 16A and 16A’ or 16B and 16B’). In other of the examples disclosed herein, each enrichment channel 18 is an area defined between one sequencing surface (e.g., 12 or 14) and a lid. The fluids described herein can be introduced into and removed from the enrichment channel(s) 18. Each enrichment channel 18 may be isolated from each other enrichment channel 18 in a flow cell 10 so that fluid introduced into any particular enrichment channel 18 does not flow into any adjacent enrichment channel 18.
- each enrichment channel 18 may be isolated from each other enrichment channel 18 in a flow cell 10 so that fluid introduced into any particular enrichment channel 18 does not
- a portion of the enrichment channel 18 may be defined in the substrate 16 using any suitable technique that depends, in part, upon the material(s) of the substrate 16.
- a portion of the enrichment channel 18 is etched into a glass substrate 16.
- a portion of the enrichment channel 18 may be patterned into a resin 22, 22’ of a multi-layered substrate 16B, 16B’ using photolithography, nanoimprint lithography, etc.
- a separate material e.g., material 24 in Fig. 1 B and Fig. 1C
- the separate material defines at least a portion of the walls of the enrichment channel 18.
- the enrichment channel 18 has a rectilinear configuration.
- the length and width of the enrichment channel 18 may be smaller, respectively, than the length and width of the substrate 16 so that portion of the substrate surface surrounding the enrichment channel 18 is available for attachment to another substrate 16.
- the width of each enrichment channel 18 can be at least about 1 mm, at least about 2.5 mm, at least about 5 mm, at least about 7 mm, at least about 10 mm, or more.
- the length of each enrichment channel 18 can be at least about 10 mm, at least about 25 mm, at least about 50 mm, at least about 100 mm, or more.
- the width and/or length of each enrichment channel 18 can be greater than, less than or between the values specified above.
- the enrichment channel 18 is square (e.g., 10 mm x 10 mm).
- each enrichment channel 18 can be as small as a few monolayers thick, for example, when microcontact, aerosol, or inkjet printing is used to deposit a separate material that defines the flow channel walls.
- the depth of each enrichment channel 18 can be about 1 pm, about 10 pm, about 50 pm, about 100 pm, or more. In an example, the depth may range from about 10 pm to about 100 pm. In another example, the depth is about 5 pm or less. It is to be understood that the depth of each enrichment channel 18 be greater than, less than or between the values specified above.
- the depth of the enrichment channel 18 may also vary along the length and width of the flow cell 10, e.g., when a patterned sequencing surface 14, 14’ is used.
- Fig. 1 B illustrates a cross-sectional view of the flow cell 10 including non- patterned opposed sequencing surfaces 12, 12’.
- each of these surfaces 12, 12’ may be prepared on the substrate 16A, 16A’, and then the substrates 16A, 16A may be attached to one another to form an example of the flow cell 10.
- Any suitable bonding material 24, such as an adhesive, a radiation- absorbing material that aids in bonding, etc., may be used to bond the substrates 16A, 16B together.
- each substrate 16A, 16A may have a concave region 26, 26’ defined therein where the components of the sequencing surface 12, 12’ may be introduced. It is to be understood that any space within the concave region 26, 26’ not occupied by the components of the sequencing surface 12, 12’ may be considered to be part of the enrichment channel 18.
- the sequencing surfaces 12, 12’ include a polymeric hydrogel 28, 28’, amplification primers 30, 30’ attached to the polymeric hydrogel 28, 28’, and enrichment capture sites 32, 32’.
- PAZAM and some other forms of the acrylamide copolymer are represented by the following structure (I): wherein:
- R A is selected from the group consisting of azido, optionally substituted amino, optionally substituted alkenyl, optionally substituted alkyne, halogen, optionally substituted hydrazone, optionally substituted hydrazine, carboxyl, hydroxy, optionally substituted tetrazole, optionally substituted tetrazine, nitrile oxide, nitrone, sulfate, and thiol;
- R B is H or optionally substituted alkyl;
- R c , R d , and R E are each independently selected from the group consisting of H and optionally substituted alkyl; each of the -(CH 2 ) P - can be optionally substituted; p is an integer in the range of 1 to 50; n is an integer in the range of 1 to 50,000; and m is an integer in the range of 1 to 100,000.
- the molecular weight of PAZAM and other forms of the acrylamide copolymer may range from about 5 kDa to about 1500 kDa or from about 10 kDa to about 1000 kDa, or may be, in a specific example, about 312 kDa.
- PAZAM and other forms of the acrylamide copolymer are linear polymers. In some other examples, PAZAM and other forms of the acrylamide copolymer are a lightly cross-linked polymers.
- the polymeric hydrogel 28, 28’ may be a variation of the structure (I).
- the acrylamide unit may be replaced with N,N- dimethylacrylamide ( ).
- the acrylamide unit in structure (I) may be replaced with , where R°, R E , and R F are each H or a C1-C6 alkyl, and R G and R H are each a C1-C6 alkyl (instead of H as is the case with the acrylamide).
- q may be an integer in the range of 1 to 100,000.
- the N,N-dimethylacrylamide may be used in addition to the acrylamide unit.
- structure (I) may include in addition to the recurring “n” and “m” features, where R d , R e , and R F are each H or a C1-C6 alkyl, and R G and R H are each a C1-C6 alkyl.
- q may be an integer in the range of 1 to 100,000.
- the polymeric hydrogel 28, 28’ may include a recurring unit of each of structure (III) and (IV): wherein each of R 1a , R 2a , R 1b and R 2b is independently selected from hydrogen, an optionally substituted alkyl or optionally substituted phenyl; each of R 3a and R 3b is independently selected from hydrogen, an optionally substituted alkyl, an optionally substituted phenyl, or an optionally substituted C7-C14 aralkyl; and each L 1 and L 2 is independently selected from an optionally substituted alkylene linker or an optionally substituted heteroalkylene linker.
- polymeric hydrogel 28, 28’ may be used to form the polymeric hydrogel 28, 28’, as long as they are functionalized to graft oligonucleotide primers 30, 30’ thereto.
- suitable polymer layers include those having a colloidal structure, such as agarose; or a polymer mesh structure, such as gelatin; or a cross-linked polymer structure, such as polyacrylamide polymers and copolymers, silane free acrylamide (SFA), or an azidolyzed version of SFA.
- suitable polyacrylamide polymers may be synthesized from acrylamide and an acrylic acid or an acrylic acid containing a vinyl group, or from monomers that form [2+2] photo-cycloaddition reactions.
- suitable polymeric hydrogels 28, 28’ include mixed copolymers of acrylamides and acrylates.
- a variety of polymer architectures containing acrylic monomers may be utilized in the examples disclosed herein, such as branched polymers, including star polymers, star-shaped or star-block polymers, dendrimers, and the like.
- the monomers e.g., acrylamide, etc.
- a mixture of the polymeric hydrogel 28, 28’ may be generated and then applied to the respective substrates 16A, 16A (having the concave regions 26, 26’ defined therein).
- the polymeric hydrogel 28, 28’ may be present in a mixture (e.g., with water or with ethanol and water). The mixture may then be applied to the respective substrate surfaces (including in the concave regions 26, 26’) using spin coating, or dipping or dip coating, or flow of the material under positive or negative pressure, or another suitable technique.
- These types of techniques blanketly deposit the polymeric hydrogel 28, 28’ on the substrate respective substrates 16A, 16A (e.g., in the concave regions 26, 26’ and on interstitial regions 34, 34’ adjacent thereto).
- Other selective deposition techniques e.g., involving a mask, controlled printing techniques, etc. may be used to specifically deposit the polymeric hydrogel 28, 28’ in the concave regions 26, 26’ and not on the interstitial regions 34, 34’.
- the substrate surface (including the concave regions 26, 26’) may be activated, and then the mixture (including the polymeric hydrogel 28, 28’) may be applied thereto.
- a silane or silane derivative e.g., norbornene silane
- the substrate surface may be exposed to plasma ashing to generate surface-activating agent(s) (e.g., -OH groups) that can adhere to the polymeric hydrogel 28, 28’.
- the applied mixture may be exposed to a curing process.
- curing may take place at a temperature ranging from room temperature (e.g., about 25°C) to about 95°C for a time ranging from about 1 millisecond to about several days.
- Polishing may then be performed in order to remove the polymeric hydrogel 28, 28’ from the interstitial regions 34, 34’ at the perimeter of the concave regions 26, 26’, while leaving the polymeric hydrogel 28, 28’ on the surface in the concave regions 26, 26’ at least substantially intact.
- the sequencing surfaces 12, 12’ also include amplification primers 30,
- a grafting process may be performed to graft the amplification primers 30, 30’ to the polymeric hydrogel 28, 28’ in the concave regions 26, 26’.
- the amplification primers 30, 30’ can be immobilized to the polymeric hydrogel 28, 28’ by single point covalent attachment at or near the 5' end of the primers 30, 30’. This attachment leaves i) an adapter-specific portion of the primers 30, 30’ free to anneal to its cognate sequencing-ready nucleic acid fragment and ii) the 3' hydroxyl group free for primer extension. Any suitable covalent attachment may be used for this purpose.
- terminated primers examples include alkyne terminated primers (e.g., which may attach to an azide surface moiety of the polymeric hydrogel 28, 28’), or azide terminated primers (e.g., which may attach to an alkyne surface moiety of the polymeric hydrogel 28, 28’).
- primers 30, 30’ include P5 and P7 primers used on the surface of commercial flow cells sold by lllumina Inc. for sequencing on HISEQTM, HISEQXTM, MISEQTM, MISEQDXTM, MINISEQTM, NEXTSEQTM, NEXTSEQDXTM, NOVASEQTM, GENOME ANALYZERTM, ISEQTM, and other instrument platforms. Both P5 and P7 primers may be grafted to each of the polymeric hydrogels 28, 28’.
- grafting may involve flow through deposition (e.g., using a temporarily bound lid), dunk coating, spray coating, puddle dispensing, or by another suitable method that will attach the primer(s) 30, 30’ to the polymeric hydrogel 28, 28’.
- a primer solution or mixture which may include the primer(s) 30, 30’, water, a buffer, and a catalyst.
- the primers 30, 30’ react with reactive groups of the polymeric hydrogel 28, 28’ in the concave region 26, 26’ and have no affinity for the surrounding substrate 16A, 16A’.
- the primers 30, 30’ selectively graft to the polymeric hydrogel 28, 28’.
- the enrichment capture site 32, 32’ includes a chemical capture agent that is attached to or applied on at least a portion of the polymeric hydrogel 28, 28’.
- a chemical capture agent that is attached to or applied on at least a portion of the polymeric hydrogel 28, 28’.
- the chemical capture agent may be biotin, which can attach streptavidin-containing target capture beads 36 to the flow cell sequencing surface(s) 12, 12’ or 14, 14’.
- the chemical capture agent may be another member of a binding pair (e.g., other than the biotin-streptavidin binding pair).
- the target capture beads 36 may include two different binding pair members, e.g., i) streptavidin (which binds to biotin to attach the capture probes 40), and ii) another member, which can bind to the chemical capture agent of the enrichment capture site 32, 32’ on the sequencing surface 12, 12’ or 14, 14’ of the flow cell 10.
- the chemical capture agent may be a non-biotin member of a binding pair, where the other member of the binding pair is attached to the solid support 38 in addition to the streptavidin.
- free functional groups (e.g., those not attached to primers 30, 30’) of the polymeric hydrogel 28, 28’ may be functionalized with the chemical capture agent so that several enrichment capture sites 32, 32’ are formed across the surface of the polymeric hydrogel 28, 28’.
- alkyne-PEG- biotin linkers or alkyne-biotin free azide groups may be covalently attached to free azides on the polymeric hydrogel 28, 28’ using click chemistry.
- primers that are complementary to the amplification primers 30, 30’ may have the chemical capture agent (e.g., biotin or another member of a binding pair) attached thereto. These complementary primers may be hybridized to some of the amplification primers 30, 30’ to form the enrichment capture sites 32, 32’.
- the chemical capture agent may be deposited in a desirable location using microcontact printing, aerosol printing, etc. to form the enrichment capture site(s) 32, 32’.
- a mask e.g., a photoresist
- the chemical capture agent may then be deposited, and the mask removed (e.g., via lift-off, dissolution, or another suitable technique).
- the enrichment capture site 32, 32’ may include a monolayer or thin layer of the chemical capture agent.
- Fig. 1 C illustrates a cross-sectional view of the flow cell 10 including patterned opposed sequencing surfaces 14, 14’.
- each of these surfaces 14, 14’ may be prepared on the substrate 16B, 16B’, and then the substrates 16B, 16B’ may be attached to one another (e.g., via material 24) to form an example of the flow cell 10.
- the flow cell 10 includes the multi-layer substrate 16B, 16B’, each of which includes the support 20, 20’ and the patterned material 22, 22’ positioned on the support 20, 20’.
- the patterned material 22, 22’ defines depressions 42, 42’ separated by interstitial regions 34, 34’.
- the patterned material 22, 22’ is respectively positioned on the support 20, 20’. It is to be understood that any material that can be selectively deposited, or deposited and patterned to form the depressions 42, 42’ and the interstitial regions 34, 34’ may be used for the patterned material 22, 22’.
- an inorganic oxide may be selectively applied to the support 20, 20’ via vapor deposition, aerosol printing, or inkjet printing.
- suitable inorganic oxides include tantalum oxide (e.g., Ta 2 0 5 ), aluminum oxide (e.g., AI 2 O 3 ), silicon oxide (e.g., Si0 2 ), hafnium oxide (e.g., Hf0 2 ), etc.
- a resin may be applied to the support 20, 20’ and then patterned.
- Suitable deposition techniques include chemical vapor deposition, dip coating, dunk coating, spin coating, spray coating, puddle dispensing, ultrasonic spray coating, doctor blade coating, aerosol printing, screen printing, microcontact printing, etc.
- Suitable patterning techniques include photolithography, nanoimprint lithography (NIL), stamping techniques, embossing techniques, molding techniques, microetching techniques, printing techniques, etc.
- suitable resins include a polyhedral oligomeric silsesquioxane resin (commercially available under the tradename POSS® from Hybrid Plastics)-based resin, a non- polyhedral oligomeric silsesquioxane epoxy resin, a polyethylene glycol) resin, a polyether resin (e.g., ring opened epoxies), an acrylic resin, an acrylate resin, a methacrylate resin, an amorphous fluoropolymer resin (e.g., CYTOP® from Bellex), and combinations thereof.
- POSS® polyhedral oligomeric silsesquioxane resin
- polyhedral oligomeric silsesquioxane refers to a chemical composition that is a hybrid intermediate (e.g., RSiOi .5 ) between that of silica (Si0 2 ) and silicone (R 2 SiO).
- a polyhedral oligomeric silsesquioxane can be that described in Kehagias et al., Microelectronic Engineering 86 (2009), pp. 776-778, which is incorporated by reference in its entirety.
- the composition is an organosilicon compound with the chemical formula [RSi0 3/2 ] n , where the R groups can be the same or different.
- Example R groups for polyhedral oligomeric silsesquioxane include epoxy, azide/azido, a thiol, a polyethylene glycol), a norbornene, a tetrazine, acrylates, and/or methacrylates, or further, for example, alkyl, aryl, alkoxy, and/or haloalkyl groups.
- the resin composition disclosed herein may comprise one or more different cage or core structures as monomeric units.
- the patterned material 22, 22’ includes the depressions 42, 42’ respectively defined therein, and interstitial regions 34, 34’ separating adjacent depressions 42, 42’.
- Many different layouts of the depressions 42, 42’ may be envisaged, including regular, repeating, and non-regular patterns.
- the depressions 42, 42’ are disposed in a hexagonal grid for close packing and improved density.
- Other layouts may include, for example, rectilinear (rectangular) layouts, triangular layouts, and so forth.
- the layout or pattern can be an x-y format of depressions 42, 42’ that are in rows and columns.
- the layout or pattern can be a repeating arrangement of depressions 42, 42’ and/or interstitial regions 34, 34’.
- the layout or pattern can be a random arrangement of depressions 42, 42’ and/or interstitial regions 34, 34’.
- the pattern may include wells, stripes, swirls, lines, triangles, rectangles, circles, arcs, checks, plaids, diagonals, arrows, squares, and/or cross-hatches.
- the layout or pattern of the depressions 42, 42’ may be characterized with respect to the density of the depressions 42, 42’ (e.g., number of depressions 42, 42’) in a defined area.
- the depressions 42, 42’ may be present at a density of approximately 2 million per mm 2 .
- the density may be tuned to different densities including, for example, a density of about 100 per mm 2 , about 1 ,000 per mm 2 , about 0.1 million per mm 2 , about 1 million per mm 2 , about 2 million per mm 2 , about 5 million per mm 2 , about 10 million per mm 2 , about 50 million per mm 2 , or more, or less.
- the density of depressions 42, 42’ in the patterned material 22, 22’ can be between one of the lower values and one of the upper values selected from the ranges above.
- a high density array may be characterized as having depressions 42, 42’ separated by less than about 100 nm
- a medium density array may be characterized as having depressions 42, 42’ separated by about 400 nm to about 1 pm
- a low density array may be characterized as having depressions 42, 42’ separated by greater than about 1 pm. While example densities have been provided, it is to be understood that any suitable densities may be used.
- the density of the depressions 42, 42’ may depend, in part, on the depth of the depressions 42, 42’.
- spacing between depressions 42, 42’ may be even greater than the examples listed herein.
- the layout or pattern of the depressions 42, 42’ may also or alternatively be characterized in terms of the average pitch, or the spacing from the center of the depression 42, 42’ to the center of an adjacent depression 42, 42’ (center-to-center spacing) or from the right edge of one depression 42, 42’ to the left edge of an adjacent depression 42, 42’ (edge-to-edge spacing).
- the pattern can be regular, such that the coefficient of variation around the average pitch is small, or the pattern can be non-regular in which case the coefficient of variation can be relatively large.
- the average pitch can be, for example, about 50 nm, about 0.1 pm, about 0.5 pm, about 1 pm, about 5 pm, about 10 pm, about 100 pm, or more or less.
- the average pitch for a particular pattern of depressions 42, 42’ can be between one of the lower values and one of the upper values selected from the ranges above.
- the depressions 42, 42’ have a pitch (center-to- center spacing) of about 1 .5 pm. While example average pitch values have been provided, it is to be understood that other average pitch values may be used.
- each depression 42, 42’ may be characterized by its volume, opening area, depth, and/or diameter.
- Each depression 42, 42’ can have any volume that is capable of confining at least some fluid that is introduced into the flow cell 10.
- the minimum or maximum volume can be selected, for example, to accommodate the throughput (e.g., multiplexity), resolution, nucleotides, or analyte reactivity expected for downstream uses of the flow cell 10.
- the volume can be at least about 1 x10 ⁇ 3 pm 3 , at least about 1 x10 ⁇ 2 pm 3 , at least about 0.1 pm 3 , at least about 1 pm 3 , at least about 10 pm 3 , at least about 100 pm 3 , or more.
- the volume can be at most about 1 x10 4 pm 3 , at most about 1 x10 3 pm 3 , at most about 100 pm 3 , at most about 10 pm 3 , at most about 1 pm 3 , at most about 0.1 pm 3 , or less.
- the area occupied by each depression opening can be selected based upon similar criteria as those set forth above for the volume.
- the area for each depression opening can be at least about 1 c 10 3 pm 2 , at least about 1 x10 2 pm 2 , at least about 0.1 pm 2 , at least about 1 pm 2 , at least about 10 pm 2 , at least about 100 pm 2 , or more.
- the area can be at most about 1 x10 3 pm 2 , at most about 100 pm 2 , at most about 10 pm 2 , at most about 1 pm 2 , at most about 0.1 pm 2 , at most about 1 x10 2 pm 2 , or less.
- the area occupied by each depression opening can be greater than, less than or between the values specified above.
- the depth of each depression 42, 42’ can be large enough to house some of the polymeric hydrogel 28, 28’.
- the depth may be at least about 0.1 pm, at least about 0.5 pm, at least about 1 pm, at least about 10 pm, at least about 100 pm, or more.
- the depth can be at most about 1 x10 3 pm, at most about 100 pm, at most about 10 pm, or less.
- the depth is about 0.4 pm.
- the depth of each depression 42, 42’ can be greater than, less than or between the values specified above.
- the diameter or length and width of each depression 42, 42’ can be at least about 50 nm, at least about 0.1 pm, at least about 0.5 pm, at least about 1 pm, at least about 10 pm, at least about 100 pm, or more. Alternatively or additionally, the diameter or length and width can be at most about 1 x10 3 miti, at most about 100 miti, at most about 10 miti, at most about 1 miti, at most about 0.5 miti, at most about 0.1 miti, or less (e.g., about 50 nm). In some examples, the diameter is or each of the length and the width is about 0.4 miti. The diameter or length and width of each depression 42, 42’ can be greater than, less than or between the values specified above.
- At least some of components of the sequencing surface 14, 14’ may be introduced into the depressions 42, 42’. It is to be understood that any space within the depressions 42, 42’ not occupied by the components of the sequencing surface 14, 14’ may be considered to be part of the enrichment channel 18.
- the polymeric hydrogel 28, 28’ is positioned within each of the depressions 42, 42’.
- the polymeric hydrogel 28, 28’ may be applied as described in reference to Fig. 1 B, so that the polymeric hydrogel 28, 28’ is present in the depressions 42, 42’ and not present on the surrounding interstitial regions 34, 34’ or enrichment capture site(s) 32, 32’.
- the primers 30, 30’ may be grafted to the polymeric hydrogel 28, 28’ within each of the depressions 42, 42’.
- the primers 30, 30’ may be applied as described in reference to Fig. 1 B, and thus will graft to the polymeric hydrogel 28, 28’ and not to the surrounding interstitial regions 34, 34’ or enrichment capture site(s) 32, 32’.
- the enrichment capture site 32, 32’ is a chemical capture agent that is applied on at least some of the interstitial regions 34, 34’.
- the chemical capture agent may be deposited on at least some of the interstitial regions 34, 34’ using microcontact printing, aerosol printing, etc. to form the enrichment capture site(s) 32, 32’.
- a mask e.g., a photoresist
- the chemical capture agent may then be deposited, and the mask removed (e.g., via lift-off, dissolution, or another suitable technique).
- the enrichment capture site 32, 32’ is a chemical capture agent that is attached to free functional groups (e.g., those not attached to primers 30, 30’) of the polymeric hydrogel 28, 28’.
- the enrichment capture site 32, 32’ is a chemical capture agent that is attached to primers that are hybridized to some of the amplification primers 30, 30’. In these examples, the enrichment capture site 32, 32’ will be present in the depressions 42, 42’ and not on the interstitial regions 34, 34’.
- any examples of the chemical capture agent disclosed herein may be used in the example shown in Fig. 1C.
- the chemical capture agent may be biotin or another member of a binding pair, depending, in part, how the solid support 38 of the target capture beads 36 is functionalized.
- the substrates 16A and 16A’ or 16B and 16B’ are attached to one another so that the sequencing surfaces 12 and 12’ or 14 and 14’ face each other with the enrichment channel 18 defined therebetween.
- the substrates 16A and 16A’ or 16B and 16B’ may be bonded to each other at some of all of the interstitial regions 34, 34’.
- the bond that is formed between the substrates 16A and 16A or 16B and 16B’ may be a chemical bond, or a mechanical bond (e.g., using a fastener, etc.).
- any suitable technique such as laser bonding, diffusion bonding, anodic bonding, eutectic bonding, plasma activation bonding, glass frit bonding, or other methods known in the art may be used to bond the substrates 16A and 16A’ or 16B and 16B’ together.
- a spacer layer e.g., material 24
- the spacer layer may be any material 24 that will seal at least some portion of the substrates 16A and 16A’ or 16B and 16B’ together.
- the spacer layer can be a radiation absorbing material that aids in bonding.
- a lid may be bonded to one of the substrate 16A or 16A so that the flow cell 10 has one sequencing surface 12 or 14.
- preparation of the library fragments may take place outside of the flow cell 10.
- any suitable library preparation technique may be used that fragments a longer piece of genetic material and incorporates the desired adapters to the ends of the fragments.
- One example of a DNA library preparation technique involves tagmentation on a solid support.
- the solid support may be any of the examples set forth herein for the target capture bead 36, and tagged library fragments are immobilized on the surface of the solid support.
- the solid support has a transposome complexes immobilized thereon, where each transposome complex includes a transposase bound to a first polynucleotide, wherein the first polynucleotide includes (i) a 3’ portion including a transposon end sequence, and (ii) a first tag (adapter).
- a DNA sample is exposed to the solid support under conditions whereby the DNA sample is fragmented by the transposome complexes, and the 3’ transposon end sequence of the first polynucleotide is transferred to a 5’ end of one strand of the fragments. This produces an immobilized library of double-stranded fragments wherein at least one strand is 5’- tagged with the first tag.
- Fig. 2 generally illustrates this library preparation method.
- the solid support 38’ includes surface bound transposome complexes 44.
- the transposome complex 44 includes oligonucleotides (which are grafted to the solid support 38’, and some of which contain the ME sequence) and a transposase enzyme non-covalently bound to the oligonucleotides.
- the density of these surface bound transposomes 44 can be modulated by varying the density of the grafted oligonucleotides containing the ME sequence or by the amount of transposase added to the solid support 38’.
- the transposome complexes 44 are present on the solid support 38’ at a density of at least 10 3 , 10 4 , 10 5 , or at least 10 6 complexes per mm 2 .
- the transposome complexes 44 When a double stranded DNA sample 37 is added to the solid support 38’, the transposome complexes 44 will tagment the added DNA, thus generating double stranded fragments 46 coupled at both ends to the surface of the solid support 38’ (e.g., via the inserted tags).
- the length of bridged fragments 46 can be varied by changing the density of the transposome complexes 44 on the surface.
- the length of the resulting bridged fragments is less than 100 base pairs (bp), 200 bp, 300 bp, 400 bp, 500 bp, 600 bp, 700 bp, 800 bp, 900 bp, 1 ,000 bp, 1 ,100 bp, 1 ,200 bp, 1 ,300 bp, 1 ,400 bp, 1 ,500 bp, 1 ,600 bp, 1 ,700 bp, 1 ,800 bp, 1 ,900 bp, 2,000 bp, 2,100 bp, 2,200 bp, 2,300 bp, 2,400 bp,
- the application of the double stranded DNA sample 37 may involve adding a biological sample to the solid support 38’.
- the biological sample can be any type that contains DNA and which can be deposited onto the solid surface 38’ for tagmentation.
- the sample can contain DNA in a variety of states of purification, including purified DNA.
- the sample need not be completely purified, and can contain, for example, DNA mixed with protein, other nucleic acid species, other cellular components and/or any other contaminant.
- the biological sample may contain a mixture of DNA, protein, other nucleic acid species, other cellular components and/or any other contaminant present in approximately the same proportion as found in vivo. The components may be in the same proportion as found in an intact cell.
- the biological sample has a 260/280 ratio of less than 2.0, 1 .9, 1.8, 1 .7, 1 .6, 1.5, 1 .4, 1.3, 1.2, 1.1 , 1 .0, 0.9, 0.8, 0.7, or less than 0.60.
- the biological sample has a 260/280 ratio of at least 2.0, 1.9, 1 .8, 1.7, 1 .6, 1.5, 1.4, 1.3, 1.2, 1.1 , 1.0, 0.9, 0.8, 0.7, or at least 0.60. Because the methods provided herein allow DNA to be bound to a solid support 38’, other contaminants can be removed merely by washing the solid support after surface bound tagmentation occurs.
- the biological sample can include, for example, a crude cell lysate or whole cells. For example, a crude cell lysate that is applied to a solid support 38’ in this example library preparation method, need not have been subjected to one or more of the separation steps that are traditionally used to isolate nucleic acids from other cellular components.
- the biological sample can comprise, for example, blood, plasma, serum, lymph, mucus, sputum, urine, semen, cerebrospinal fluid, bronchial aspirate, feces, and macerated tissue, or a lysate thereof, or any other biological specimen comprising DNA.
- Fig. 3A and 3B illustrate the tagmentation reaction according to one example.
- transposomes 44 include a dimer of Tn5 with each monomer 50 binding a double stranded molecule, e.g., the ME adaptor.
- One strand 48 of the ME adaptor is covalently attached to the surface of a solid support 38’.
- Transposomes 44 bind the sample DNA and generate two nicks in the DNA backbone, creating fragments 46.
- the nicks are 9 bases apart on either strand. It is to be understood that the transposome 44 can generate a gap of 7, 8, 9, 10, 11 , or 12 bp between nicks.
- One of the two strands (e.g., strand 48) of each ME adaptor is ligated to the 5' end of each fragment 46 at each nick position.
- This strand 48 is referred to as “the transferred strand” and is grafted to the surface of the solid support 38’ via its 5' end.
- the resulting bridge of the surface tagmentation of Fig. 3A is redrawn in Fig. 3B to clarify the nature of the resulting bridge.
- the transferred strand 48 may include a first sequencing primer sequence (e.g., a read 1 sequencing primer sequence) and a first sequence (P5’) that is complementary to at least a portion of one of the amplification primers (e.g., P5) on the flow cell sequencing surface 12, 14.
- a first sequencing primer sequence e.g., a read 1 sequencing primer sequence
- P5 first sequence
- tagmentation introduces one adapter (or tag) to each DNA fragment 46.
- the transposase enzyme may be removed via sodium dodecyl sulfate (SDS) treatment or heat or proteinase K digestion. Removal of the transposase enzymes leaves the fragments 46 attached to the solid support 38’.
- SDS sodium dodecyl sulfate
- the non-transferred strands 48’ of the ME adaptors are adapters that are not incorporated into the DNA fragments 46 during tagmentation, but rather, may be subsequently ligated to the other end of each fragment 46.
- the non-transferred strands 48’ may be attached to the transferred strand 48 via base-pairing.
- the non-transferred strand 48’ is an adapter (or tag) including a second sequencing primer sequence (e.g., a read 2 sequencing primer sequence) and a second sequence (P7) that is identical to the at least a portion of another of the amplification primers (P7) on the flow cell sequencing surface 12, 14.
- the identical sequence enables the formation of a copy that is complementary to at least a portion of one of the amplification primers (e.g., PI) on the flow cell sequencing surface 12, 14.
- ligation L may be performed to incorporate a non-transferred strand 48’ into each DNA fragment 46 at an end opposite where the transferred strand 48 is incorporated.
- one of the adapters e.g., including a first sequencing primer sequence and a first sequence (P5’) that is complementary to at least a portion of one of the amplification primers (e.g., P5) on the flow cell sequencing surface 12, 14) may be bound to the surface of the solid support 38’.
- a transposome complex may also be bound to the solid support 38’.
- a partial Y-adapter Prior to loading the transposome complex on the solid support 16, a partial Y-adapter may be mixed with a transposase enzyme (e.g., including two Tn5 molecules) to form an example of the transposome complex.
- the partial Y-adapter may include two mosaic end sequences that are hybridized to each other. One of the mosaic end sequences has a free end that is able to attach to the fragmented DNA strands 46 during tagmentation, and thus is similar to the transferred strand 48 in Fig. 3A and Fig. 3B.
- the other of the mosaic end sequences may be attached to a second sequencing primer sequence (e.g., a read 2 sequencing primer sequence), and a second sequence (P7) that has the same sequence as at least a portion of another of the amplification primers (P7) on the flow cell sequencing surface 12, 14, so that its copy is complementary (e.g., P7’) to the amplification primer (P7).
- a second sequencing primer sequence e.g., a read 2 sequencing primer sequence
- P7 a second sequence that has the same sequence as at least a portion of another of the amplification primers (P7) on the flow cell sequencing surface 12, 14, so that its copy is complementary (e.g., P7’) to the amplification primer (P7).
- the other of the mosaic end sequences, the second sequencing primer sequence and the second sequence make up an adapter sequence that is not attached to the fragmented DNA strands during tagmentation, and thus are similar to the non-transferred strands 48’ in Fig. 3A and Fig. 3
- Loading the transposome complex on the solid support 38’ may involve mixing the transposome complex with the solid support 38’, and exposing the mixture to suitable conditions for ligating the mosaic end of the partial Y-adapter to the 3’-end of the adapter sequence on the solid support 38’.
- a tagmentation process may then be performed.
- the DNA sample 37 may be applied to the solid support 38’. As the sample contacts the transposome complexes, the longer nucleic acid sample 37 is tagmented.
- the sample 36 is fragmented into fragments 64, and each of the fragments 64 is tagged, at its 5’ end, with the free end of the mosaic end of the partial Y-adapter.
- Successive tagmentation of the longer nucleic acid sample 37 results in a plurality of bridged molecules between the transposome complexes.
- the bridged molecules wrap around the solid support 38’.
- the transposase enzyme may be removed, and further extension and ligation is undertaken to ensure sample fragments are attached to the non-attached adapter sequence partial Y-adapter.
- a nucleotide library is created in a tube with adapters attached thereto, and then the library is attached to the solid support 38’ through hybridization of the adapters to primers on the solid support 38’.
- adapter sequences having one member of a binding pair may added to the library fragments in the tube, and then the sequencing-ready library fragments are bound to the solid support 38’ in the tube.
- Library preparation that takes place off of the flow cell may also involve a ribonucleic acid (RNA) sample.
- RNA ribonucleic acid
- the RNA sample is first converted to a complementary deoxyribonucleic acid (cDNA) sample.
- cDNA complementary deoxyribonucleic acid
- reverse transcription which utilizes a reverse transcriptase enzyme.
- a kit for reverse transcription and second strand synthesis is used.
- the high capacity cDNA reverse transcription kit from ThermoFisher Scientific, may be used.
- a kit for reverse transcription and template switch (for the second strand) is used.
- the template switching RT enzyme mix from New England Biolabs, may be used.
- any DNA library preparation method including those described herein, may be used to add adapters/tags to the fragments 46 to generate sequencing-ready nucleic acid fragments attached to the solid support 38’.
- Library Preparation on the Flow Cell including those described herein, may be used to add adapters/tags to the fragments 46 to generate sequencing-ready nucleic acid fragments attached to the solid support 38’.
- Examples of the flow cell 10 shown in Fig. 1A, Fig. 1 B, and Fig. 1C may also be included in a combined library preparation and analysis system 52.
- This system 52, and the flow cell 10’ included therein, are shown schematically in Fig. 4.
- the flow cell 10’ includes one or more preparation channels 54, 54’ upstream of the enrichment channel 18.
- the enrichment channel 18 may be any of the examples disclosed herein for the flow cell 10 that include the sequencing surface 12 or 14 and the enrichment capture sites 32, 32’.
- the system 52 includes a flow cell reagent system 56 in selective fluid communication with at least the enrichment channel 18.
- the flow cell reagent system 56 may include reservoirs 58, 60, 62, fluidic channels (e.g., transport channel 64), pumps, valves, and other fluidic device components that can control the flow of reagents to and from the different channels 18, 54, 54’ of the flow cell 10’.
- the preparation channels 54, 54’ are utilized for on-flow cell library preparation.
- the flow cell 10’ may include the DNA library preparation channel 54 upstream of, and in selective fluid communication with the enrichment channel 18.
- the flow cell 10’ may include both the RNA library preparation channel 54’ and the DNA library preparation channel 54 (which are in fluid communication with each other).
- the DNA library preparation channel 54 is upstream of, and in selective fluid communication with the enrichment channel 18; and the RNA library preparation channel 54’ is upstream of, and in selective fluid communication with the DNA library preparation channel 54.
- the flow cell 10’ may include any example of the substrate 16, where the preparation channel(s) 54, 54’ is/are defined in a first region and the enrichment channel 18 is defined in a second region. Because they are defined in different regions of the substrate 16, the architecture and component(s) within the channels 54, 54’ and/or 18 may be different.
- the DNA library preparation channel 54 may be defined between two substrates 16, or between one substrate 16 and a lid.
- the region of the substrate(s) 16 that defines the DNA library preparation channel(s) 54 may be non-patterned (similar to substrate 16B, 16B’), and may be functionalized to include preparation capture sites (not shown), which temporarily attach the solid supports 38’ used for library preparation.
- the surface(s) of the substrate region(s) defining the DNA library preparation channel 54 is/are coated with a binding pair member (e.g., avidin, streptavidin, biotin, lectin, carbohydrate, nucleic acid binding protein, epitope, antibody, etc.) that is capable of binding to the other binding pair member that is located on the solid support 38’ used for library preparation.
- a binding pair member e.g., avidin, streptavidin, biotin, lectin, carbohydrate, nucleic acid binding protein, epitope, antibody, etc.
- Each binding pair member is one preparation capture site.
- the surface(s) of the substrate region(s) defining the DNA library preparation channel 54 is/are coated with oligonucleotides (oligos) that have biotinylated oligos hybridized thereto.
- the biotinylated oligos are preparation capture sites that are capable of temporarily attaching the solid supports 38’ used for library preparation.
- the preparation capture sites may be capable of any other form of chemical coupling, which can attach the solid support 38’ to the surface(s) of the DNA library preparation channel 54.
- DNA library preparation may be performed in the DNA library preparation channel 54, and thus the DNA library preparation channel 54 does not include the amplification primers 30, 30’.
- the reservoir 58 is shown as being in selective fluid communication with the DNA library preparation channel 54.
- This reservoir 58 may include different chambers to selectively deliver a DNA sample 37 and a library preparation fluid to the DNA library preparation channel 54 so that library preparation may take place within the channel 54.
- the library preparation fluid may include library preparation beads (including the solid support 38’ and the transposomes 44 attached thereto as described in reference to Fig. 2 and 3A).
- the solid supports 38’ may bind to the preparation capture sites, and DNA library preparation may take place, for example, using the tagmentation method described herein.
- the reservoir 58 may also deliver different fluids to the DNA library preparation channel 54, depending upon the library preparation method to be used.
- Some examples of the flow cell 10’ include the RNA library preparation channel 54’ upstream of the DNA library preparation channel 54.
- the RNA library preparation channel 54’ may be defined between two substrates 16, or between one substrate 16 and a lid.
- the region of the substrate(s) 16 that defines the RNA library preparation channel(s) 54’ may be non- patterned (similar to substrate 16B, 16B’).
- the RNA library preparation channel 54’ may be used for the initial preparation of an RNA sample, and thus the RNA library preparation channel 54’ does not include the amplification primers 30, 30’.
- the initial process of RNA library preparation may be performed in the RNA library preparation channel 54’.
- the reservoir 60 is shown as being in selective fluid communication with the RNA library preparation channel 54’.
- This reservoir 60 may include different chambers to selectively deliver an RNA sample and a library preparation fluid to the RNA library preparation channel 54’ so that RNA may be converted to cDNA within the channel 54’.
- the library preparation fluid may include a reverse transcriptase and reagent(s) for second strand synthesis.
- the library preparation fluid may include a reverse transcriptase and reagent(s) for template switch (for the second strand).
- the cDNA prepared in the RNA library preparation channel 54’ may then be delivered (e.g., via a transport channel) to the DNA library preparation channel 54.
- the cDNA may be tagmented to incorporate adapters (tags) and to generate sequencing ready nucleic acid fragments attached to the solid supports 38 within the DNA library preparation channel 54.
- any other any suitable DNA library preparation technique may be performed on the cDNA in the DNA library preparation channel 54.
- the DNA library preparation channel 54 is in selective fluid communication with the enrichment channel 18.
- the transport channel 64 selectively and fluidically connects the preparation channel 54 and the enrichment channel 18, so that the sequencing-ready nucleic acid fragments can be delivered to the enrichment channel 18 for capture, amplification and sequencing.
- An example enrichment method includes preparing library fragments from the genomic deoxyribonucleic acid or the complementary deoxyribonucleic acid; introducing the library fragments to the enrichment channel 18; and incubating the enrichment channel 18 at a predetermined temperature, whereby at least some of the library fragments including the targeted region hybridize to the capture probes 40.
- the target capture beads 36 disclosed herein may be pre-attached to the enrichment capture sites 32, 32’ in the flow cell 10, 10’, or may be introduced (e.g., by a user of the flow cell 10, 10’) to the enrichment channel 18 as part of an enrichment and sequencing workflow.
- the target capture beads 36 may be included into the enrichment channel 18 in an enrichment fluid (e.g., a salt buffer containing the target capture beads 36).
- an enrichment fluid e.g., a salt buffer containing the target capture beads 36.
- the enrichment fluid may be contained within the reservoir 62 that is in selective fluid communication with the enrichment channel 18.
- the enrichment fluid may be delivered from the reservoir 62 to the enrichment channel 18.
- the enrichment capture sites 32, 32’ immobilize some of the target capture beads 36 at the sequencing surface(s) 12, 12’ or 14, 14’ in the enrichment channel 18. It is to be understood that some target capture beads 36 may not attach to the enrichment capture sites 32, 32’, and these target capture beads 36 will be removed from the enrichment channel 18 before further processing.
- a predetermined time may be allowed to pass before removing the enrichment fluid and any non-immobilized target capture beads 36 from the enrichment channel 18. In an example, the predetermined time may range from about 5 minutes to about 30 minutes in order to obtain a desirable number of immobilized target capture beads 36. Longer incubation times may also be used.
- This example method then includes washing away the enrichment fluid and non-trapped target capture beads 36 from the enrichment channel 18.
- Washing may involve introducing a washing fluid into the enrichment channel 18.
- the flow may push any target capture beads 36 from that have not become immobilized at the enrichment capture sites 32, 32’ out through an exit port of the enrichment channel 18.
- the immobilization mechanism e.g., binding pair, hybridization, covalent bonding, etc.
- the immobilization mechanism may prevent any immobilized target capture beads 36 from becoming part of the exit flow.
- the sequencing-ready nucleic acid fragments may be released from the solid supports 38’ prior to being introduced into the enrichment channel 18.
- the release of the sequencing-ready nucleic acid fragments from the solid support 38’ may be initiated outside of the flow cell 10, 10’ using any suitable technique.
- a cleaving agent may be introduced, and a stimulus may be applied to trigger the cleaving agent to release the sequencing-ready nucleic acid fragments from the solid support 38’.
- the release of the sequencing-ready nucleic acid fragments may involve heating the solid supports 38’ above a melting temperature of a primer that is hybridized to the sequencing-ready nucleic acid fragments.
- heating may be used to dissociate the fragments from one another.
- the released sequencing-ready nucleic acid fragments may be separated from the solid supports 38’.
- the release of the sequencing-ready nucleic acid fragments from the solid support 38’ may be initiated in the DNA library preparation channel 54 using any suitable technique (e.g., cleaving agent and stimulus, heating, etc.).
- the solid supports 38’ may remain attached to the preparation capture sites in the DNA library preparation channel 54, and thus the released sequencing-ready nucleic acid fragments may be transported from the DNA library preparation channel 54 into the enrichment channel 18.
- the single- stranded sequencing-ready nucleic acid fragments Prior to being introduced into the enrichment channel 18, the single- stranded sequencing-ready nucleic acid fragments may have blockers attached to the adapters at each end. The blockers may be selected to reduce adapter-to- primer hybridization.
- the blockers may at least reduce hybridization of the sequencing-ready nucleic acid fragments to the flow cell primers 30, 30’.
- the blockers are XGEN® Universal Blockers available from Integrated DNA Technologies.
- Fig. 5 schematically illustrates the introduction of the end-blocked sequencing-ready nucleic acid fragments 66, 66’ to the enrichment channel 18 having the target capture beads 36 immobilized at the enrichment capture sites 32.
- Some of the end-blocked sequencing-ready nucleic acid fragments 66’ include the target library fragment, while others of the end-blocked sequencing-ready nucleic acid fragments 66 include a non-target library fragment (e.g., a fragment of the DNA sample that is not of interest for the particular analysis).
- the capture probes 40 have a sequence that is complementary to the target library fragment end-blocked sequencing-ready nucleic acid fragments 66’, at least some of the end-blocked sequencing-ready nucleic acid fragments 66’ respectively hybridize to the capture probes 40. In contrast, the other end-blocked sequencing-ready nucleic acid fragments 66 will not hybridize to the capture probes 40, as the sequences of their non-target library fragments are non-complementary to the capture probes 40. Moreover, the blockers can prevent the end-blocked sequencing-ready nucleic acid fragments 66, 66’ from hybridizing to the flow cell primers 30.
- the end-blocked sequencing-ready nucleic acid fragments 66, 66’ may be allowed to incubate in the enrichment channel 18 for a time and at a temperature so that hybridization occurs between the target library fragments and the capture probes 40.
- the incubation time may range from about 5 minutes to about 2 hours. In an example, the incubation time is about 1 .5 hours.
- the incubation temperature may range from about 50°C to about 55°C. In an example, the incubation temperature is about 50°C.
- a crowding reagent may be introduced with the sequencing-ready nucleic acid fragments 66, 66’.
- Example crowding reagents include dextran sulfate and polyethylene glycol. These crowding reagents can help to crowd the sequencing-ready nucleic acid fragments 66, 66’ to the target capture beads 36.
- an electric field may be applied to the enrichment channel 18 during the incubation of the sequencing-ready nucleic acid fragments 66, 66’.
- the electric field may be applied using electrodes integrated into the flow cell 10, 10’ or using external electrodes. The electric field can help to move the sequencing-ready nucleic acid fragments 66, 66’ to the target capture beads 36.
- the method may include inducing movement of a fluid containing the sequencing-ready nucleic acid fragments 66, 66’ during the incubation.
- the enrichment channel 18 may include brushes, pillars, or other three-dimensional structures on the surface that can facilitate fluid movement.
- electrophoresis may be used to pre-concentrate the sequencing-ready nucleic acid fragments 66, 66’ in the enrichment channel 18.
- isotachophoresis ITP may be used to speed up hybridization.
- ITP may be used to concentrate the sequencing-ready nucleic acid fragments 66, 66’ into a narrow band width, e.g., a 1000x higher concentration than the concentration with ITP. This will drive the hybridization kinetics significantly, and thus the hybridization time (e.g., from about 1 .5 hours to about 15 minutes).
- Any example of the method may then include washing away the end- blocked sequencing-ready nucleic acid fragments 66 from the enrichment channel 18. Washing may involve introducing a washing fluid into the enrichment channel 18. The flow may push any fragments 66 or 66 and 66’ that have not hybridized to capture probes 40 out through an exit port of the enrichment channel 18.
- the immobilization mechanism e.g., hybridization
- between the end-blocked sequencing-ready nucleic acid fragments 66’ and the capture probes 40 of the target capture beads 36 may prevent any immobilized end-blocked sequencing- ready nucleic acid fragments 66’ from becoming part of the exit flow.
- flow rate(s) and/or temperature(s) may be programmed to enhance i) capture probe 40-target library fragment hybridization efficiency and ii) washing processes in order to minimize binding of fragments 66 that include non-target library fragments.
- the immobilized end-blocked sequencing-ready nucleic acid fragments 66’ may then be denatured from the capture probes 40. Denaturation may be accomplished in a seeding reagent (e.g., a salt buffer) and at a suitable denaturing temperature.
- the denaturing temperature may range from about 70°C to about 92°C, depending upon the seeding reagent utilized. In an example, the denaturing temperature is about 92°C.
- the denaturing temperature may be higher than the temperature needed to remove the blockers. As such, denaturing may remove the blockers and an additional removal process would not be utilized.
- the end-blocked sequencing-ready nucleic acid fragments 66’ are released in the enrichment channel 18, there is minimal to no loss of the released fragments 66’. As such, post-enrichment PCR is not utilized.
- the eluted fragments 66’ (each of which includes the target library fragment) are then seeded across the sequencing surface(s) 12, 12’ or 14, 14’. Seeding is accomplished through hybridization between a sequence of the adapters/tags of the fragment 66’ and a complementary one of the primers 30, 30’. Seeding may be performed at a suitable hybridization temperature for the fragment 66’ and the primer(s) 30, 30’.
- the location at which the sequencing-ready nucleic acid fragments 66’ seed within the flow cell 10 depends, in part, upon how the primers 30, 30’ are attached.
- the released sequencing-ready nucleic acid fragments 66’ will seed across polymeric hydrogels 28, 28’ in the concave regions 26, 26’.
- the released sequencing-ready nucleic acid fragments 66’ will seed across polymeric hydrogels 28, 28’ within each of the depressions 42, 42’.
- the solid supports 38 of the target capture beads 36 may then be removed from the enrichment channel 18. Removal of the solid supports 38 may involve any suitable technique, which depends upon the mechanism used to attach the target capture beads 36 to the enrichment capture sites 32, 32’. As examples, denaturing, bond cleaving, etc. may be used.
- the seeded sequencing-ready nucleic acid fragments 66’ can then be amplified using cluster generation.
- the sequencing-ready nucleic acid fragments 66’ are copied from the hybridized primers 30, 30’ by 3’ extension using a high-fidelity DNA polymerase.
- the original sequencing-ready nucleic acid fragments 66’ are denatured, leaving the copies immobilized to the sequencing surfaces 12, 12’ or 14, 14’.
- the copies include the sequence of the target library fragment. Isothermal bridge amplification or some other form of amplification may be used to amplify the immobilized copies.
- the copied templates loop over to hybridize to an adjacent, complementary primer 30, 30’, and a polymerase copies the copied templates to form double stranded bridges, which are denatured to form two single stranded strands.
- a sequencing primer may be introduced that hybridizes to a complementary sequence on the template polynucleotide strand. This sequencing primer renders the template polynucleotide strand ready for sequencing.
- the 3’- ends of the templates and any flow cell-bound primers 30, 30’ may be blocked to prevent interference with the sequencing reaction, and in particular, to prevent undesirable priming.
- an incorporation mix may be added to the enrichment channel 18.
- the incorporation mix includes a liquid carrier, a polymerase, and fluorescently labeled nucleotides.
- the fluorescently labeled nucleotides may include a 3’ OH blocking group.
- the fluorescently labeled nucleotides are added to the sequencing primer (thereby extending the sequencing primer) in a template dependent fashion such that detection of the order and type of nucleotides added to the sequencing primer can be used to determine the sequence of the template. More particularly, one of the nucleotides is incorporated, by a respective polymerase, into a nascent strand that extends the sequencing primer and that is complementary to the template polynucleotide strand. In other words, in at least some of the template polynucleotide strands across the enrichment channel 18, respective polymerases extend the hybridized sequencing primer by one of the nucleotides in the incorporation mix.
- the incorporation of the nucleotides can be detected through an imaging event.
- an illumination system (not shown) may provide an excitation light to the respective sequencing surfaces 12, 12’ or 14, 14’.
- the nucleotides can further include a reversible termination property (e.g., the 3’ OH blocking group) that terminates further primer extension once a nucleotide has been added to the sequencing primer.
- a reversible termination property e.g., the 3’ OH blocking group
- a nucleotide analog having a reversible terminator moiety can be added to the sequencing primer such that subsequent extension cannot occur until a deblocking agent is delivered to remove the moiety.
- a deblocking reagent can be delivered to the enrichment channel 18 after detection occurs.
- Wash(es) may take place between the various fluid delivery steps.
- the SBS cycle can then be repeated n times to extend the sequencing primer by n nucleotides, thereby detecting a sequence of length n.
- the forward strands may be sequenced and removed, and then reverse strands are constructed and sequenced as described herein.
- SBS has been described in detail, it is to be understood that the flow cells 10, 10’ described herein may be utilized with other sequencing protocol, for genotyping, or in other chemical and/or biological applications.
- kits may be used to perform on-flow cell target enrichment disclosed herein.
- kits includes: a library preparation fluid including library preparation beads, each library preparation bead including a first solid support 38’; and a transposome 44 attached to the first solid support 38’; a sample fluid including a genomic deoxyribonucleic acid sequence; and an enrichment fluid including target capture beads 36, each target capture bead 36 including a second solid support 38; and capture probes 40 attached to the second solid support 38, each of the capture probes 40 including a single stranded deoxyribonucleic acid sequence that is complementary to a targeted region of the genomic deoxyribonucleic acid in the sample fluid.
- the first solid support 38’ and the second solid support 38 are individually selected from the group consisting of a magnetically responsive material, a glass, a polymer, and a metal.
- the capture probes 40 may be attached to the second solid support 38 through a binding pair. Any of the binding pairs disclosed herein may be used.
- kits also include a blocking fluid, which includes blocking deoxyribonucleic acid sequences.
- the blocking fluid may be used to block sequencing-ready nucleic acid fragments 66, 66’ before they are introduced into the enrichment channel 18 of a flow cell 10, 10’.
- kits include: an RNA to cDNA conversion sub-kit; and an enrichment fluid including target capture beads 36, each target capture bead 36 including: a solid support 38; and capture probes 40 attached to the solid support 38, each of the capture probes 40 including a single stranded deoxyribonucleic acid sequence that is complementary to a targeted region of cDNA generated using the RNA to cDNA conversion sub-kit.
- This example kit may also include a library preparation fluid including library preparation beads, each library preparation bead including a first solid support 38’; and a transposome 44 attached to the first solid support 38’.
- the capture probes 40 may be attached to the solid support 38 through a binding pair. Any of the binding pairs disclosed herein may be used.
- a target region of the PhiX genome was selected and single stranded capture probes with a sequence complementary to the target region were prepared.
- the target region included genomic coordinate 3194, and the capture probe size was 69 nucleotides.
- the capture probes were biotinylated at one end.
- the NEXTERATM PhiX library (from lllumina Inc.) was prepared and blockers (from Integrated DNA Technologies) were added to the library. The final concentration of the blocked library was about 2 pM. This library was split in two tubes. [00205] For the comparative enrichment method, the biotinylated capture probes (0.02 mM / 1.5 pL / total 1.8E+10 probes) were incubated for about 1.5 hours with the library fragments in one of the tubes to allow hybridization between the library fragments including the target region and the biotinylated capture probes.
- the tube contents were then exposed to streptavidin beads (M280, 6E+06 beads), where the hybridized probes/fragments became bound to the beads via the biotin label of the capture probes.
- streptavidin beads M280, 6E+06 beads
- the beads were then separated from non-captured library fragments using a magnetic force.
- the beads were then loaded on a non-patterned flow cell functionalized with alkyne PEG-biotin and P5/P7 primers.
- the beads (with the captured hybridized probes/fragments) were immobilized at the alkyne PEG- biotin sites through free streptavidin sites on the beads.
- the library fragments were eluted off the beads in a saline sodium citrate buffer with sodium dodecyl sulfate at about 92°C for about 2 minutes, and then the temperature was dropped to about 40°C for about 5 minutes for seeding.
- the biotinylated capture probes (0.02 mM / 1.5 pL / total 1.8E+10 probes) were incubated for about 1 (one) hour with the streptavidin beads (M280, 6E+06 beads). The biotinylated capture probes became bound to the beads via the biotin label.
- the beads (with the captured biotinylated capture probes) were then loaded on a non-patterned flow cell functionalized with alkyne PEG-biotin and P5/P7 primers. The beads (with the captured biotinylated capture probes) were immobilized at the alkyne PEG-biotin sites through free streptavidin sites on the beads.
- the library fragments in the other of the tubes were loaded onto the flow cell and were allowed to incubate for about 1.5 hours to allow hybridization between the library fragments including the target region and the biotinylated capture probes on the bead surfaces.
- a washing process was performed to remove non-bound library fragments.
- the bound library fragments were eluted off the beads in a saline sodium citrate buffer with sodium dodecyl sulfate at about 92°C for about 2 minutes, and then the temperature was dropped to about 40°C for about 5 minutes for seeding.
- Fig. 6 depicts a relative coverage plot of the clustered target library fragments on the flow cell surface when the comparative enrichment method was used, and on the flow cell surface when the example enrichment method was used.
- the relative coverage plot is the relative read depth at a locus (%, Y axis) versus the genomic coordinate.
- the relative coverage plot indicates that the capture probes effectively hybridize the library fragments including the target region, in both the comparative method and the example method.
- the example method simplifies the workflow (compared to the comparative method) and also achieves target enrichment.
- the target region was from the TRUSIGHTTM Tumor 170 panel (from lllumina Inc.).
- Single stranded capture probes with a sequence complementary to the target region were prepared.
- the capture probes were biotinylated at one end.
- biotinylated capture probes were incubated for about 1 (one) hour with the streptavidin beads (M280) to achieve a probe density of about 3.13E+05 capture probes/bead).
- the biotinylated capture probes became bound to the beads via the biotin label.
- the beads (with the captured biotinylated capture probes) were then loaded on a non-patterned flow cell functionalized with alkyne PEG-biotin and P5/P7 primers.
- the beads (with the captured biotinylated capture probes) were immobilized at the alkyne PEG-biotin sites through free streptavidin sites on the beads.
- the NEXTERATM Flex library preparation kit (lllumina Inc.) was used with Human-NA 12878 samples (from Coriell Life Sciences) to prepare the library, and blockers (from Integrated DNA Technologies) were added to the library.
- the library fragments were loaded onto the flow cell and were allowed to incubate for about 2 hours at about 50°C to allow hybridization between the library fragments including the target region and the biotinylated capture probes on the surfaces of the immobilized beads.
- a washing process was performed to remove non-bound library fragments.
- the bound library fragments were eluted off the beads in a saline sodium citrate buffer with sodium dodecyl sulfate at about 92°C for about 2 minutes, and then the temperature was dropped to about 40°C for about 5 minutes for seeding.
- the library fragments were eluted off the beads in a saline sodium citrate buffer with sodium dodecyl sulfate at 92°C for about 2 minutes, and then the temperature was dropped to about 40°C for about 5 minutes for seeding.
- the target region was from the TRUSIGHTTM Tumor 170 panel (from lllumina Inc.).
- Single stranded capture probes with a sequence complementary to the target region were prepared.
- the capture probes were biotinylated at one end.
- the biotinylated capture probes became bound to the beads via the biotin label.
- the bead samples (with the captured biotinylated capture probes) were then respectively loaded on three different non-patterned flow cell functionalized with alkyne PEG-biotin and P5/P7 primers.
- the beads were immobilized at the alkyne PEG- biotin sites through free streptavidin sites on the beads.
- the NEXTERATM Flex library preparation kit (lllumina Inc.) was used with Human-NA 12878 samples (from Coriell Life Sciences) to prepare the library, and blockers (from Integrated DNA Technologies) were added to the library.
- the library fragments were loaded onto the different flow cell and were allowed to incubate for about 2 hours at about 50°C to allow hybridization between the library fragments including the target region and the biotinylated capture probes on the surfaces of the immobilized beads.
- a washing process was performed to remove non-bound library fragments.
- the bound library fragments were eluted off the beads in a saline sodium citrate buffer with sodium dodecyl sulfate at about 92°C for about 2 minutes, and then the temperature was dropped to about 40°C for about 5 minutes for seeding.
- the flow cell was washed to remove the beads, and clustering was performed using isothermal amplification. Sequencing was then performed, and sequencing reads were obtained. The targeted cluster count was determined by dividing the number of reads by 2.
- ranges provided herein include the stated range and any value or sub-range within the stated range, as if they were explicitly recited.
- a range represented by from about 2 mm to about 300 mm should be interpreted to include not only the explicitly recited limits of from about 2 mm to about 300 mm, but also to include individual values, such as about 15 mm, 22.5 mm, 245 mm, etc., and sub-ranges, such as from about 20 mm to about 225 mm, etc.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966351P | 2020-01-27 | 2020-01-27 | |
PCT/US2021/014919 WO2021154648A2 (en) | 2020-01-27 | 2021-01-25 | Kit, system, and flow cell |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3969610A2 true EP3969610A2 (en) | 2022-03-23 |
Family
ID=76969806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21707071.3A Pending EP3969610A2 (en) | 2020-01-27 | 2021-01-25 | Kit, system, and flow cell |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210230585A1 (en) |
EP (1) | EP3969610A2 (en) |
JP (1) | JP2023511465A (en) |
KR (1) | KR20220131819A (en) |
CN (1) | CN114207128A (en) |
AU (1) | AU2021213088A1 (en) |
BR (1) | BR112021026701A2 (en) |
CA (1) | CA3145540A1 (en) |
IL (1) | IL289120A (en) |
MX (1) | MX2021015805A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022354606A1 (en) * | 2021-09-30 | 2024-04-11 | Illumina, Inc. | Blocker methods |
WO2023223033A1 (en) * | 2022-05-18 | 2023-11-23 | Oxford Nanopore Technologies Plc | Compositions and methods for nucleic acid extraction and purification |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013117595A2 (en) * | 2012-02-07 | 2013-08-15 | Illumina Cambridge Limited | Targeted enrichment and amplification of nucleic acids on a support |
US20140005066A1 (en) * | 2012-06-29 | 2014-01-02 | Advanced Liquid Logic Inc. | Multiplexed PCR and Fluorescence Detection on a Droplet Actuator |
US9683230B2 (en) * | 2013-01-09 | 2017-06-20 | Illumina Cambridge Limited | Sample preparation on a solid support |
WO2014145555A1 (en) * | 2013-03-15 | 2014-09-18 | Lariat Biosciences, Inc. | Microfluidic methods for manipulating dna |
US9944924B2 (en) * | 2014-01-16 | 2018-04-17 | Illumina, Inc. | Polynucleotide modification on solid support |
WO2016189331A1 (en) * | 2015-05-28 | 2016-12-01 | Illumina Cambridge Limited | Surface-based tagmentation |
IL263118B2 (en) * | 2017-02-21 | 2023-12-01 | Illumina Inc | Tagmentation using immobilized transposomes with linkers |
CN112074739A (en) * | 2018-05-02 | 2020-12-11 | 哈恩-席卡德应用研究学会 | Immunoassay for automated systems |
CR20190591A (en) * | 2018-06-29 | 2020-02-26 | Illumina Cambridge Ltd | Flow cells |
-
2021
- 2021-01-25 BR BR112021026701A patent/BR112021026701A2/en unknown
- 2021-01-25 AU AU2021213088A patent/AU2021213088A1/en active Pending
- 2021-01-25 CA CA3145540A patent/CA3145540A1/en active Pending
- 2021-01-25 KR KR1020217042260A patent/KR20220131819A/en unknown
- 2021-01-25 MX MX2021015805A patent/MX2021015805A/en unknown
- 2021-01-25 JP JP2021577073A patent/JP2023511465A/en active Pending
- 2021-01-25 EP EP21707071.3A patent/EP3969610A2/en active Pending
- 2021-01-25 CN CN202180004114.1A patent/CN114207128A/en active Pending
- 2021-01-26 US US17/158,926 patent/US20210230585A1/en active Pending
- 2021-12-19 IL IL289120A patent/IL289120A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3145540A1 (en) | 2021-08-05 |
MX2021015805A (en) | 2022-04-01 |
IL289120A (en) | 2022-02-01 |
CN114207128A (en) | 2022-03-18 |
JP2023511465A (en) | 2023-03-20 |
KR20220131819A (en) | 2022-09-29 |
US20210230585A1 (en) | 2021-07-29 |
BR112021026701A2 (en) | 2022-08-02 |
AU2021213088A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022518082A (en) | Flow cell | |
US20220410146A1 (en) | Flow cells | |
US20220080415A1 (en) | Flow cells | |
US20210230585A1 (en) | Kit, system, and flow cell | |
WO2021154648A2 (en) | Kit, system, and flow cell | |
US20210238589A1 (en) | Biotin-streptavidin cleavage composition and library fragment cleavage | |
US20220195519A1 (en) | Immobilization in flow cells | |
RU2804754C2 (en) | Immobilization in flow cuvetes | |
US11975325B2 (en) | Nucleic acid capture, concentration, and purification | |
EP3931355B1 (en) | Time-based cluster imaging of amplified contiguity preserved liarary fragments of genomic dna | |
KR20210120822A (en) | sequencing kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211217 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060386 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240207 |